The formation of the University of California Neuroscape Psychedelics Division will help advance psychedelic research on brain health through $6.4 million in private financing.
The new division at UCSF will employ a translational research approach that will integrate psychedelic treatment with groundbreaking neuroscience technology. The first project to be undertaken will be a MAPS phase 3 trial for the evaluation of MDMA, commonly known as ecstasy, as a new PTSD treatment.
Neuroscape executive director Adam Gazzaley stated that the financiers of the center are helping facilitate a great leap forward in producing evidence of the clinical safety and effectiveness of psychedelics for individuals who use psychedelics to treat various mental health conditions, which include addiction, PTSD, anxiety and depression. Neuroscape is a UCSF multidisciplinary research center that bridges the gap between technology and neuroscience.
Gazzaley stated that the center employed a closed-loop, neuroscience-based approach to developing experiential medicine. A good example of this would be a video game that has been cleared by the FDA as a medical therapeutic. He noted that they were excited to use their approach in understanding how they could deliver psychedelic treatments in a precise and more personalized manner.
The new division in Neuroscape will have Robin Carhart-Harris as its founding director. Carhart-Harris is the founder of the first psychedelic research center at Imperial College London and among the most cited researchers in the field of psychedelic science.
Carhart-Harris, who is also the current UCSF Ralph Metzner Distinguished Professor of Neurology and Psychiatry, revealed that the establishment of this new division was an exciting development in the psychedelics field. He added that he was delighted to be joining the Neuroscape team and he hoped to guide the new division to huge successes.
More than half a billion individuals across the globe suffer from debilitating mental health issues, which creates a need for new clinical tools. In the recent past, a lot of progress has been made, especially in terms of mechanisms of action of some psychedelic treatments such as psilocybin and MDMA being granted Breakthrough Therapy Designation by the FDA for the treatment of depression and PTSD, respectively.
Despite this, however, not much research has been done on approaches that could optimize the delivery of these treatments. Research that explores how to enhance the impact of these treatments while recording physiological, psychological and neural data is also lacking.
This is where the new psychedelics division at Neuroscape comes in, as it will place focus on the various elements that shape the experience of patients. UCSF associate professor of neurology and psychiatry Jennifer Mitchell, who will lead the MDMA clinical trials, noted that their objective was to dynamically alter primary contextual elements in a way that helped guide patients toward an optimum experience.
Psychedelics are attracting a lot of interest in the research community; for example, the pipeline of about 50 psychedelic molecules being studied by Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) is aimed at shortlisting those that warrant detailed study for commercialization purposes.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.